Analysts expect that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post $1.95 billion in sales for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Regeneron Pharmaceuticals’ earnings. The lowest sales estimate is $1.87 billion and the highest is $2.05 billion. Regeneron Pharmaceuticals posted sales of $1.66 billion in the same quarter last year, which suggests a positive year over year growth rate of 17.5%. The firm is scheduled to report its next quarterly earnings report on Tuesday, November 5th.
On average, analysts expect that Regeneron Pharmaceuticals will report full year sales of $7.60 billion for the current financial year, with estimates ranging from $7.34 billion to $7.77 billion. For the next fiscal year, analysts anticipate that the business will post sales of $8.34 billion, with estimates ranging from $7.32 billion to $8.73 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.60 by $0.69. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. The business had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the business posted $5.45 EPS. The company’s quarterly revenue was up 20.3% compared to the same quarter last year.
A number of equities analysts recently commented on the stock. TheStreet downgraded shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Wednesday, June 5th. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals to $344.00 and set a “market perform” rating for the company in a research note on Wednesday, August 7th. Argus lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 18th. Cowen reissued a “hold” rating and issued a $353.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, July 29th. Finally, ValuEngine lowered Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, June 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $396.88.
In other news, major shareholder Sanofi sold 172,904 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total transaction of $48,611,959.60. Insiders own 11.84% of the company’s stock.
A number of large investors have recently made changes to their positions in REGN. Vanguard Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 0.9% during the second quarter. Vanguard Group Inc. now owns 6,079,347 shares of the biopharmaceutical company’s stock valued at $1,902,835,000 after acquiring an additional 54,247 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 3.5% during the second quarter. Invesco Ltd. now owns 1,344,273 shares of the biopharmaceutical company’s stock valued at $420,759,000 after acquiring an additional 46,055 shares in the last quarter. American Century Companies Inc. increased its stake in Regeneron Pharmaceuticals by 3.7% during the 1st quarter. American Century Companies Inc. now owns 1,041,044 shares of the biopharmaceutical company’s stock valued at $427,473,000 after purchasing an additional 37,573 shares in the last quarter. Northern Trust Corp increased its stake in Regeneron Pharmaceuticals by 0.6% during the 2nd quarter. Northern Trust Corp now owns 978,518 shares of the biopharmaceutical company’s stock valued at $306,275,000 after purchasing an additional 5,530 shares in the last quarter. Finally, Parnassus Investments CA increased its stake in Regeneron Pharmaceuticals by 290.6% during the 2nd quarter. Parnassus Investments CA now owns 625,000 shares of the biopharmaceutical company’s stock valued at $195,625,000 after purchasing an additional 465,000 shares in the last quarter. 66.54% of the stock is currently owned by institutional investors.
Shares of NASDAQ:REGN traded up $4.27 during trading hours on Friday, hitting $277.73. The company’s stock had a trading volume of 38,684 shares, compared to its average volume of 653,114. The company has a market capitalization of $30.90 billion, a price-to-earnings ratio of 14.02, a P/E/G ratio of 1.28 and a beta of 1.13. Regeneron Pharmaceuticals has a 52 week low of $271.37 and a 52 week high of $442.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.88 and a quick ratio of 3.11. The firm’s fifty day moving average price is $290.75 and its 200 day moving average price is $324.31.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.